Werkgroep Cardiologische centra Nederland

BROADWAY (Recruiting)

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or ASCVD and LDL-C >70 and <100 mg/dL Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
Medicine
Obicetrapib
Population
ASCVD
Phase
III
Starting year
2021

Director of Study

dr. F.M.A.C. Martens (Cardioloog)
Deventer, Deventer Ziekenhuis